|
|
Article: Aphton Bankruptcy News Blasts Stock; Igeneon Also Facing Risk.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
The sliding fortune of Aphton Corp. shifted seismically for the worse, and investors fled on word that the company has filed for Chapter 11 bankruptcy.
Aphton's stock (Pink Sheets:APHT) closed Wednesday at 3 cents, down 10 cents, or more than 77 percent.
Serious trouble began more than a year ago, when the firm's pancreatic cancer drug Insegia missed its primary endpoint in a Phase III trial. Insegia (G17DT immunogen) targets gastrin and is designed to spur the immune system's production of antibodies to the growth hormone and its receptor. The company's stock, then trading on Nasdaq, dropped $1.43 to close at $1.70. A ...
Related newspaper, magazine, and journal articles:
|
|
Article: APHTON RELEASES PHASE III DATA, PREPARES FOR REGULATORY ...
BIOWORLD Today;
March 5, 2003 ;
700+ words
... ... agreement. Also in December, Aphton sold about 1.5 million shares ... million. As of Sept. 30, Aphton had $8.3 million in cash ... financial options, Gevas told BioWorld Today. He believes Aphton will "have more than one option ...
|
|